Prostate-specific membrane antigen (PSMA) is central to this, enabling sensitive disease localisation with PSMA-positron emission tomography/computed tomography (PSMA-PET/CT) and lesion-directed radioligand therapy (RLT) using α-β-emitting agents for patients with prostate cancer (PCa) [1,2]. The gene discussed is FOLH1; the disease is prostate cancer.